GlassScriptPhysician profile
Justin Reno
NPI 1518223130
$3,551.50
in general payments reported to CMS, 2019-2025
32 companies · $713 in 2025
The $713 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $53.28 · 2021: $398 · 2022: $829 · 2023: $797 · 2024: $762 · 2025: $713.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,054.01 | 2021-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $329.56 | 2021-2025 | |
| Lilly USA, LLC | $239.64 | 2021-2024 | Mounjaro, Zepbound, Jardiance |
| Pfizer INC. | $223.38 | 2021-2025 | |
| Lundbeck LLC | $213.97 | 2022-2025 | Rexulti, Vyepti |
| Otsuka America Pharmaceutical, INC. | $185.76 | 2022-2025 | Rexulti |
| Astellas Pharma US INC | $170.09 | 2021-2025 | Veozah, Myrbetriq |
| Ultragenyx Pharmaceutical INC. | $160.47 | 2022-2024 | Crysvita |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.57 | 2021-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $92.34 | 2021-2023 | Synjardy, Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $89.16 | 2021-2025 | Trintellix |
| Amgen INC. | $83.02 | 2022-2025 | Otezla, Repatha, Krystexxa |
| Hologic Sales and Service, LLC | $64.15 | 2024-2025 | Aptima |
| Phathom Pharmaceuticals, INC. | $58.95 | 2025 | Voquezna |
| Astrazeneca Pharmaceuticals LP | $55.88 | 2022-2025 | Breztri, Airsupra |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Shield Therapeutics INC | $51.51 | 2022-2023 | Accrufer |
| Sumitomo Pharma America, INC. | $44.07 | 2025 | Gemtesa |
| Abbott Laboratories | $38.93 | 2021-2024 | Freestyle Libre 3 |
| Nevro Corp. | $32.78 | 2022 | |
| Inspire Medical Systems, INC. | $30.50 | 2025 | Inspire |
| Amarin Pharma, INC. | $26.95 | 2019-2021 | |
| Eisai INC. | $21.22 | 2021 | |
| Amneal Pharmaceuticals LLC | $19.00 | 2022 | |
| Xeris Pharmaceuticals, INC. | $18.94 | 2023 | Gvoke Hypopen |
| Daiichi Sankyo INC. | $17.59 | 2021 | |
| Axsome Therapeutics, INC. | $16.27 | 2023 | Auvelity |
| Exact Sciences Corporation | $16.03 | 2024 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $14.80 | 2019 | |
| Allergan, INC. | $13.54 | 2019 | |
| Idorsia Pharmaceuticals US INC | $13.49 | 2023 | Quviviq |
| Glaxosmithkline, LLC. | $12.69 | 2019 | |
| Echosens North America, INC. | $10.24 | 2025 | Fibroscan |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Justin Reno listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.